BillionToOne

BillionToOne is a precision diagnostics company founded in 2016, based in the United States. The company's mission revolves around revolutionizing molecular diagnostics through its proprietary molecular counting platform. This platform, capable of counting DNA molecules at the single-count level, aims to significantly enhance the accuracy and efficiency of disease detection. The recent $130.00M Series D funding, secured on 21 June 2024, saw participation from a notable group of investors including Civilization Ventures, Adams Street Partners, 50Y, Baillie Gifford, Hummingbird Ventures, Libertus Capital, Neuberger Berman Group, and PremjiInvest. The company's slogan, "We push the boundaries of molecular diagnostics through quantitative technologies," aptly captures their commitment to advancing the field of biotechnology and healthcare.